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Introduction: Fibrinogen is a key component of the coagulation cascade, and variation in its 
circulating levels may contribute to thrombotic diseases, such as venous thromboembolism 
(VTE) and ischemic stroke. Gamma prime (γ′) fibrinogen is an isoform of fibrinogen and has 
anticoagulant properties, including inhibiting thrombin and slowing platelet aggregation, that 
may affect clot formation. 
Methods: Two-sample Mendelian randomization (MR) was applied to estimate the causal 
effect of total circulating fibrinogen and its isoform, γ′ fibrinogen, on risk of VTE and 
ischemic stroke subtypes using summary statistics from published genome-wide association 
studies of fibrinogen, VTE, and ischemic stroke, and an unpublished study of γ′ fibrinogen. 
Genetic instruments for γ′ fibrinogen and total fibrinogen were selected by pruning genome-
wide significant variants to linkage disequilibrium r2 < 0.1. The inverse variance weighted 
MR approach was used to estimate effects in the main analysis, with additional approaches 
that are more robust to the inclusion of pleiotropic variants applied in sensitivity analyses, 
including MR-Egger, weighted median MR, and weighted mode MR. 
  
Results:  The main inverse variance weighted MR estimates (Figure 1) based on 16 genetic 
instruments for γ′ fibrinogen and 75 genetic instruments for total fibrinogen (Figure 2) 
indicated a protective effect of both γ′ fibrinogen and total fibrinogen on VTE risk. Higher γ′ 
fibrinogen levels decreased the risk of cardioembolic and large artery stroke. Higher total 
fibrinogen levels decreased the risk of cardioembolic stroke but increased the risk of large 
artery and small vessel stroke. Effect estimates were consistent across sensitivity analyses, 
indicating that the results are unlikely to be attributable to the inclusion of pleiotropic 
variants. 
Conclusion: Our results are consistent with effects of genetically determined γ′ 
fibrinogen on VTE and ischemic stroke. The strong inverse association found between γ′ 
fibrinogen and VTE and ischemic stroke subtypes suggests the need to evaluate γ′ 
fibrinogen’s causal effect on other cardiovascular outcomes. Further research is needed to 
explain the protective effects seen in total fibrinogen on VTE and on cardioembolic stroke.  
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BACKGROUND  
Genome-wide association studies (GWAS) for venous thromboembolism (VTE) and 
ischemic stroke have identified significant associations with genetic variants at the FGA, 
FGB, and FGG genes (Germain et al., 2015; Malik et al., 2018). These genes encode the 
subunits of a protein called fibrinogen and highlight fibrinogen as a protein that may have a 
role in the pathophysiology of these cardiovascular outcomes.  
 
Literature Review  
Pathophysiology of VTE and ischemic stroke subtypes 
VTE usually results from a fibrin-rich blood clot formed in the veins of the leg and is 
identified as either deep vein thrombosis or as pulmonary embolism (Wolberg, Monroe, 
Roberts, & Hoffman, 2003). Pulmonary embolism is a complication of deep vein thrombosis 
where the clot breaks apart and travels up into the smaller blood vessels of the lung, causing 
a blockage (Patel et al., 2017). Although deep vein thrombosis often results from the stasis of 
blood in the deep veins, some acute incidences result from hypercoagulability (Wolberg et 
al., 2003). Ischemic stroke, caused by blood vessel blockage in the brain, has several 
different subtypes, including cardioembolic stroke, large artery stroke, and small vessel 
stroke resulting from small vessel disease (Malik et al., 2018). Cardioembolic stroke occurs 
when a clot in an artery of the heart forms and travels to obstruct a vessel in the brain 
(Adams et al., 1993). Cardioembolic strokes can be caused by cardiac abnormalities, 
arrhythmias, or improperly functioning heart valves (O'Carroll & Barrett, 2017). Large artery 
stroke usually results from a clot that form in an atherosclerotic artery: when an 
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atherosclerotic plaque ruptures, this triggers the formation of a blood clot that then travels to 
the brain and obstructs one of the large arteries (Banerjee & Turan, 2017). Small vessel 
stroke is caused by occlusion of the small vessels in the brain (Traylor et al., 2015). Although 
the pathophysiology is not completely understood, small vessel strokes resulting from small 
vessel disease is associated with hypertension and seems to be highly heritable (Khan, 
Porteous, Hassan, & Markus, 2007; Traylor et al., 2015).  
 
Properties and function of fibrinogen 
Fibrinogen is a precursor of the fibrin mesh that forms blood clots; it also promotes platelet 
aggregation and acts as a regulator in inflammation (Davalos & Akassoglou, 2012; 
Mosesson, 2005). The fibrinogen molecule is encoded by FGA, FGB, and FGG genes that 
respectively form two of each of the following subunits: Aα, Bβ, and γ (Omarova et al., 
2013). The standard version of the γ chain is called γA, and typical fibrinogen includes two 
γA chains. Alternative splicing of the FGG transcript, however, results in a γ’ polypeptide 
chain that forms γA/γ’ fibrinogen and γ’/γ’ fibrinogen, which are collectively known as 
gamma prime (γ’) fibrinogen and compose up to 15% of total circulating fibrinogen levels 
(Omarova et al., 2013). The γ’ chain has a different carboxyl-terminal region than that of the 
typical γA chain, and this appears to confer it with several anticoagulant properties. This 
region in the γ’ chain binds thrombin with high-affinity and inhibits factor XIII that acts to 
stabilize a clot (Chung & Davie, 1984; Mosesson, 2003). Thrombin binding to the γ’ chain 
suppresses thrombin generation, resulting in decreased rates of fibrin formation and of 
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platelet aggregation (Lancellotti et al., 2008; Mosesson, 2005; Sidelmann, Gram, Jespersen, 
& Kluft, 2000).  
Indeed, even before the first GWAS was published, a haplotype in the FGG gene 
(FGG-H2) was found to be associated with lower levels of γ’ fibrinogen and a higher risk of 
VTE (Uitte de Willige et al., 2005). This result was later recapitulated by GWAS of VTE 
(Germain et al., 2015). More recently, a large GWAS of ischemic stroke has identified this 
same signal to also be associated with ischemic stroke, with the γ’ fibrinogen lowering allele 
being associated with a higher risk of ischemic stroke (Malik et al., 2018). This provides a 
rationale for suspecting that the apparent involvement of fibrinogen in the pathophysiology 
of VTE and ischemic stroke may be explained by the anticoagulant properties of γ’ 
fibrinogen.  
 
Epidemiological studies 
A case-control study with γ′ fibrinogen suggests an inverse association with deep vein 
thrombosis (Uitte de Willige et al., 2005). However, large prospective cohort studies, did not 
find an association between γ′ fibrinogen and VTE or stroke (Appiah, Schreiner, MacLehose, 
& Folsom, 2015; Appiah, Heckbert, Cushman, Psaty, & Folsom, 2016; Folsom et al., 2016).  
While a few case-control studies showed a correlation of total circulating fibrinogen 
with VTE risk, (Koster et al., 1994; Yamashita et al., 2014) other studies were unable to find 
an association (Hunt et al., 2018; Payne, Miller, Hooper, Lally, & Austin, 2014; Tsai et al., 
2002). With regards to ischemic stroke, elevated total fibrinogen levels have been associated 
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with an increased risk of ischemic stroke in a few prospective cohort studies (Siegerink, 
Rosendaal, & Algra, 2009) and case control studies (Kim et al., 2013; Zhang et al., 2013).  
 
Overcoming Limitations Inherent in Observational Studies  
Contradictions in the literature lead to more questions about how γ′ fibrinogen and total 
fibrinogen levels influence the risk of VTE and ischemic stroke. However, associations of γ′ 
fibrinogen and total fibrinogen with VTE and ischemic stroke detected in observational 
studies may have been influenced by confounding and reverse causation. Mendelian 
randomization (MR) can be used to overcome these limitations, by using genetic variants 
associated with fibrinogen levels as instrumental variables to assess the causal effect of γ′ 
fibrinogen and total fibrinogen levels on VTE and ischemic stroke. In an MR, genetic 
variants that measure a particular exposure are identified in order to make causal inferences 
regarding the effect of the exposure on the outcome (Davey Smith & Hemani, 2014). The 
genetic variants can be identified in a GWAS.  
Because of the independent assortment of alleles at conception, genetic variants are 
independent of environmental or behavioral factors, such that they do not act as confounders. 
Reverse causation is another limitation that is present in observational studies that MR seeks 
to overcome. Because genetics precedes incidence of disease, and disease cannot change 
genetics, interpretation of results are not limited by the possibility of reverse causation. 
Nevertheless, for an instrumental variable to be valid for MR, several assumptions must be 
made. First of all, the genetic instrument must be associated with the exposure. Secondly, the 
genetic instrument can only affect the outcome through the exposure being measured. The 
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instrument cannot directly impact disease or contribute to the disease in question through 
another pathway, nor can be it be associated with another cause of the disease (Haycock et 
al., 2016). A genetic variant that is being used as an instrumental variable can violate this 
assumption by having pleiotropic effects on other phenotypes other than the main exposure 
of interest.  
The observations discussed above about γ′ fibrinogen lowering variants in the FGG-
H2 haplotype increasing the risk of VTE and ischemic stroke already constitute a kind of 
pseudo-MR, but the application of formal MR methodology has many advantages, including 
that it allows for an estimation of the causal effect size. 
 
Hypothesis, Research Question, Specific Aims or Objectives 
This project aims to whether or not there is a significant causal association of γ′ fibrinogen 
and total fibrinogen levels with VTE and ischemic stroke. Due to the anticoagulant nature of 
γ′ fibrinogen, we hypothesized that elevated levels of genetically determined γ′ fibrinogen 
levels would decrease risk of VTE and ischemic stroke. Related to total fibrinogen, we 
hypothesized that elevated levels of genetically determined total fibrinogen would increase 
the risk of VTE and ischemic stroke based on published observational studies. To test our 
hypotheses, we performed two-sample MR leveraging the results of large-scale GWAS, to 
explore the causal effects γ′ fibrinogen and total fibrinogen on VTE and ischemic stroke. If a 
causal association is discovered, this information could be used to determine potential 
lifestyle interventions or drug targets used to prevent or treat VTE and ischemic stroke.  
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Public Health Significance 
The importance of γ′ fibrinogen is underappreciated, as evidenced by the relative lack of 
observational studies evaluating its association with cardiovascular outcomes. The 
anticoagulant effects of γ′ fibrinogen signify the need to evaluate how levels of γ′ fibrinogen 
impact cardiovascular outcomes, such as VTE and ischemic stroke. Knowing if, or how, 
genetically determined γ′ fibrinogen levels influence risk of VTE or ischemic stroke could 
pave the way for new drug targets to be used in the prevention and/or treatment of these 
outcomes.  
Total fibrinogen has been implicated in observational studies regarding 
cardiovascular outcomes. Understanding its association with cardiovascular outcomes, like 
VTE or stroke is important, and just like with γ′ fibrinogen levels, the discovery of a causal 
effect of total fibrinogen levels on these outcomes could provide the foundation for the 
creation of new therapeutic interventions.  
7 
 
JOURNAL ARTICLE 
Title of Journal Article: A Mendelian randomization study of circulating gamma prime 
fibrinogen and total fibrinogen levels on venous thromboembolism and ischemic stroke 
subtypes 
Name of Journal Proposed for Article Submission: Blood 
  
Introduction 
Fibrinogen is a key protein in coagulation, as it serves as the precursor of fibrin and promotes 
platelet aggregation (Sidelmann et al., 2000). Fibrinogen is also an inflammatory mediator 
that increases in concentration upon infection, injury, or other trauma leading to 
inflammation (Davalos & Akassoglou, 2012).  
Gamma prime (γ′) fibrinogen is a protein resulting from alternative splicing at the fibrinogen 
locus and makes up about 8-15% of total plasma fibrinogen (Farrell, 2012). γ′ fibrinogen has 
several anticoagulant properties that it does not share with other forms of fibrinogen (Chung 
& Davie, 1984; Mosesson, 2003).  
Given fibrinogen's role in coagulation, γ′ fibrinogen and total fibrinogen levels may 
affect the risk of arterial and venous thrombosis. Indeed, some observational studies have 
found higher total fibrinogen levels to be associated with an increased risk of venous 
thromboembolism (VTE) (Koster et al., 1994; Yamashita et al., 2014) and stroke (Chuang, 
Bai, Chen, Lien, & Pan, 2009; Kim et al., 2013; Siegerink et al., 2009; Zhang et al., 2013), 
although these associations are not consistent across all studies (Hunt et al., 2018; Tsai et al., 
2002). A case-control study suggests an inverse association with γ′ fibrinogen and venous 
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thrombosis (Uitte de Willige et al., 2005). Large prospective cohort studies, however, did not 
find an association between γ′ fibrinogen and VTE or stroke (Appiah et al., 2015; Appiah et 
al., 2016; Folsom et al., 2016). In genome-wide association studies (GWAS) of VTE and 
ischemic stroke, the locus encoding the fibrinogen subunit genes was found to be genome-
wide significant (Germain et al., 2015; Malik et al., 2018), and. the variant that was 
associated with a higher risk of these outcomes was associated with lower levels of γ′ 
fibrinogen (Uitte de Willige et al., 2005). 
With observational studies the association of fibrinogen and γ′ fibrinogen with VTE 
and stroke may have been influenced by confounding and reverse causation. To combat this, 
we can use Mendelian randomization (MR) to explore the causal effects of γ′ fibrinogen and 
total fibrinogen levels on VTE and ischemic stroke by leveraging the results of large-scale 
GWAS). We used two-sample MR to leverage genome-wide significant associations 
discovered in GWAS for the determination of causal effects of γ′ and total fibrinogen levels 
on VTE and ischemic stroke subtypes. 
 
Methods 
Included published GWAS 
The MR analyses used summary statistics from several GWAS, which are described in Table 
1. All of these GWAS were restricted to European-ancestry participants and were based on 
genotypes imputed using the 1000 Genomes Project phase 1 version 3 reference panel. We 
used a GWAS of circulating fibrinogen concentration by the Cohorts for Heart and Aging 
Research in Genetic Epidemiology (CHARGE). This study included 120,246 participants and 
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identified 41 genome-wide significant loci that explained 3% of variance in circulating 
plasma fibrinogen (de Vries et al., 2016). Summary statistics were then used to determine the 
effect of genetic variants on fibrinogen levels.  
To assess the effect of genetic variants on VTE, we used summary statistics from the 
largest published GWAS on VTE, by the International Network against VENous Thrombosis 
(INVENT) consortium, based on 7,507 VTE cases and 52,632 controls (Germain et al., 
2015).  
To assess the effect of genetic variants on ischemic stroke and its subtypes 
(cardioembolic strokes, large artery stroke, and small vessel stroke) a GWAS by the 
MEGASTROKE consortium based on 67,162 cases and 454,450 controls was used (Malik et 
al., 2018) (Table 1). The GWAS for stroke and VTE were restricted to European-ancestry 
individuals and based on genotype data imputed to the European samples from phase 3 of the 
1000 Genomes Project. 
 
GWAS of γ′ fibrinogen 
Summary statistics from GWAS based on the 1000 Genomes Project reference panel were 
not available for γ′ fibrinogen. Therefore, we performed a GWAS of circulating γ′ fibrinogen 
concentration in European-ancestry participants from the Atherosclerosis Risk in 
Communities (ARIC) study. γ′ fibrinogen (mg/dL) was measured from fasting citrated 
plasma collected at ARIC visit 3 using ELISA, as described previously (Appiah et al., 2015). 
γ′ fibrinogen levels were natural log transformed prior to analyses. Outliers with γ′ fibrinogen 
levels ±3 SD from the mean were excluded, resulting in a final sample size of 9,225 
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participants. Genotypes were assessed using the Affymetrix (Santa Clara, CA, USA) 
Genome-wide Human SNP Array 6.0 assay, and additional genotypes were imputed using 
IMPUTE2 (Howie, Marchini, & Stephens, 2011; Howie, Fuchsberger, Stephens, Marchini, & 
Abecasis, 2012) based on the 1000 Genomes Project phase 1 version 3 reference panel (1000 
Genomes Project Consortium et al., 2012). 
Genome-wide analyses were then performed using FAST version 1.8 (Chanda, 
Huang, Arking, & Bader, 2013), adjusted for age, sex, and ancestry-informative principal 
components 1 and 2. A total of 9,335,343 variants with minor allele frequency > 1% and 
imputation quality r2 > 0.3 were considered in the analysis.  
 
Table 1: Summary of genome-wide association studies used in the summary statistics based 
two sample Mendelian randomization analyses. 
Phenotype Sample Size Consortium Reference 
γ′ fibrinogen levels 9,225 ARIC study Unpublished 
Total fibrinogen levels 120,246 CHARGE consortium de Vries et al. 
Venous thromboembolism 7,507 cases / 52,632 controls  INVENT consortium Germain et al. 
Cardioembolic stroke 7,193 cases / 322,150 controls MEGASTROKE Malik et al. 
Large artery stroke 4,373 cases / 204,991 controls MEGASTROKE Malik et al. 
Small vessel stroke 5,386 cases / 254,558 controls MEGASTROKE Malik et al. 
Any ischemic stroke  34,217 cases / 434,418 controls MEGASTROKE Malik et al. 
 
Genetic instruments 
We separately applied the following steps to the summary statistics for circulating γ′ 
fibrinogen and fibrinogen levels. In order to obtain sets of independent genetic instruments 
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for each of these exposures, we selected all genome-wide significant variants (p < 5×10-8) 
and pruned these variants according to their pairwise linkage disequilibrium (LD) by 
removing the variant with the highest p-value from each pair of variants with a LD r2 > 0.1.  
 
Mendelian randomization - primary analysis 
The TwoSampleMR package implemented in R was used to calculate estimates from genetic 
instruments of the causal effect of the corresponding exposure (γ′ fibrinogen or total 
fibrinogen levels) on each of the outcomes VTE, , cardioembolic stroke, large artery stroke, 
small vessel stroke, and any ischemic stroke). Evidence from each of the genetic instruments 
was then combined using inverse-variance weighted (IVW) meta-analysis to produce a single 
estimate of the causal effect of each exposure on each outcome (Burgess, Butterworth, & 
Thompson, 2013). 
 
Mendelian randomization - sensitivity analyses 
Several sensitivity analyses were performed, including MR-Egger, weighted median 
estimator, and weighted mode estimator, each being robust to certain kinds of pleiotropy. If 
there is horizontal pleiotropy within the instrumental variable, a bias causal estimate can 
result. MR-Egger is used assesses whether the effect estimate is influenced by directional 
pleiotropy. It can be used even when all of the instruments are pleiotropic (Bowden, Davey 
Smith, & Burgess, 2015). Weighted median estimator is a more powerful and precise 
approach than MR-Egger, but it only gives a consistent causal effect estimate when no more 
than half of the instruments are invalid (Bowden, Davey Smith, Haycock, & Burgess, 2016). 
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The weighted mode estimator gives consistent causal effect estimates in the presence of 
horizontal pleiotropy, but only when weights associated with the valid instruments are the 
largest (Hartwig, Davey Smith, & Bowden, 2017). 
We used the global test implemented in the MR-Presso R package to detect 
heterogeneity amongst the genetic instruments. When the global test was significant (p-value 
<0.05) we removed statistically significant outliers detected by MR-Presso (p-value <0.05) 
and repeated the IVW analysis. As an additional sensitivity analysis, the Mendelian 
Randomization R package was used to perform IVW MR analyses corrected for LD between 
genetic instruments (Burgess et al., 2013). Although genetic instruments were selected to be 
independent (r2 < 0.1), this method was used to determine the effects of residual LD on our 
primary IVW analyses. As a final sensitivity analysis, we performed an MR using only 
variants at the fibrinogen gene cluster. Given that the genes near this variant encode the 
subunits of the fibrinogen protein, they may be more likely to be free of pleiotropic effects 
that do not go through fibrinogen levels.    
 
Results 
 
GWAS of γ′ fibrinogen 
In our GWAS of γ′ fibrinogen, the only locus that was associated at genome-wide 
significance (p < 5×10-8) was the fibrinogen gene cluster itself, as shown in the Manhattan 
plot in Appendix A. A total of 509 variants at this locus were associated with γ′ fibrinogen. 
The most significant variant at this locus was rs7654093 with a minor allele frequency of 
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24%. This variant was associated with a 0.2 log(mg/dL) decrease in γ′ fibrinogen levels per 
copy of the minor allele (p = 3.1×10-418).  
 
Selection of genetic instruments 
After pruning the 5,076 genome-wide significant variants for total fibrinogen levels 
according to an LD r2 threshold of 0.1, 75 independent genetic variants remained and were 
used as genetic instruments for total fibrinogen levels. 16 of these 75 variants were located at 
the fibrinogen gene cluster. After pruning the 509 genome-wide significant variants for γ′ 
fibrinogen levels, all of which were located at the fibrinogen gene cluster, 16 independent 
genetic variants remained and were used as genetic instruments for γ′ fibrinogen levels.  
 
MR of γ′ fibrinogen 
Forest plots that show the causal effect estimate produced using each individual genetic 
instrument for γ′ fibrinogen levels are shown in Appendix B. Effect estimates of genetically 
determined circulating γ′ fibrinogen levels on VTE and stroke subtypes, generated using the 
IVW approach, are shown in Figure 1. Genetically determined γ′ fibrinogen levels were 
inversely associated with the risk of VTE (ORIVW = 0.34; pIVW = 8.2×10
-28), and this 
association remained consistent across all sensitivity analyses (Appendix C Figure 1).  
Genetically determined γ′ fibrinogen levels were also inversely associated with the 
risk of cardioembolic stroke (ORIVW = 0.67; pIVW =1.4✕10-5), large artery stroke (ORIVW = 
0.64 with a pIVW = 4.3×10
-6), and any ischemic stroke (ORIVW = 0.77; pIVW = 1.7×10
-12). 
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These associations had consistent effect size and directions across sensitivity analyses 
(Appendix C). As shown in Appendix C Figure 4, genetically determined circulating γ′ 
fibrinogen levels were not associated with small vessel disease (ORIVW = 1.10 with a pIVW = 
0.29)  
 
Figure 1: Forest plot of the association of genetically determined γ′ fibrinogen levels with venous 
thromboembolism, ischemic stroke and its subtypes, using the inverse variance weighted method 
 
 
MR of total fibrinogen 
Forest plots that show the causal effect estimate produced using each individual genetic instrument 
for total fibrinogen levels are shown in Appendix D. Effect estimates of genetically determined total 
circulating fibrinogen levels on VTE and stroke subtypes, generated using the IVW approach, are 
shown in Figure 2. Genetically determined total fibrinogen levels were inversely associated with the 
risk of VTE (ORIVW = 0.15, pIVW = 2.8×10-4). As seen in Appendix E Figure 1, the effect estimates 
of the association between fibrinogen and VTE were consistent across all sensitivity analyses. 
Similarly, we found a significant inverse associated between genetically determined fibrinogen levels 
15 
 
and cardioembolic stroke (ORIVW = 0.47, pIVW = 0.039), which was also relatively consistent across 
sensitivity analyses (Appendix E Figure 2).  
Genetically determined fibrinogen levels were positively associated with small vessel stroke 
(ORIVW = 2.72, pIVW = 0.015) and large artery stroke (ORIVW = 2.49, pIVW = 0.046). Sensitivity 
analyses were consistent with a positive effect direction for small vessel stroke (Appendix E Figure 
4), but did not consistently show a positive effect direction for large artery stroke (Appendix E 
Figure 3). Finally, genetically determined fibrinogen levels were not clearly associated with any 
ischemic stroke (Figure 2 and Appendix E Figure 5).  
 
Figure 2: Forest plot of the association of genetically determined total fibrinogen levels with venous 
thromboembolism, ischemic stroke and its subtypes, using the inverse variance weighted method 
 
 
Discussion 
In this MR study we examined the effects of genetically determined circulating γ′ fibrinogen 
and total fibrinogen levels and VTE and ischemic stroke subtypes. We found that genetically 
determined circulating γ′ fibrinogen levels were associated with VTE, cardioembolic stroke, 
16 
 
and large artery stroke. Genetically determined total circulating fibrinogen levels were 
associated with VTE, cardioembolic stroke, and small vessel stroke.  
 
Comparison with observational studies 
There are conflicting results in observational studies examining the association of γ′ 
fibrinogen levels with VTE and ischemic stroke have yielded conflicting results. A large 
longitudinal study was unable to confirm that γ′ fibrinogen levels were associated with 
increased risk of VTE (Folsom et al., 2016). However, we found that high genetically 
determined γ′ fibrinogen levels were associated with lower risk of VTE. With regards to 
stroke, case-control studies have proposed an association between ischemic stroke and higher 
levels of γ′ fibrinogen (Cheung et al., 2008; van den Herik et al., 2011). However, 
prospective cohort studies were unable to find an association between plasma γ′ fibrinogen 
and ischemic stroke or any other incident cardiovascular endpoint, despite its apparent role in 
clot formation (Appiah et al., 2015; Appiah et al., 2016). From these studies it has been 
suggested that γ′ fibrinogen levels may increase in response to inflammation resulting from 
an incident cardiac event, such as ischemic stroke. In contrast to these results from 
observation studies, we found that high genetically determined γ′ fibrinogen levels were 
associated with a lower risk of cardioembolic and large artery stroke. 
 There are conflicting results in observational studies examining the association of 
total fibrinogen levels with VTE and ischemic stroke. While a few case-control studies 
showed a positive correlation of plasma fibrinogen with VTE risk, (Koster et al., 1994; 
Yamashita et al., 2014) other studies were unable to find an association, (Hunt et al., 2018; 
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Payne et al., 2014; Tsai et al., 2002). In contrast, our MR results consistently suggest that 
high genetically determined fibrinogen levels are associated with lower risk of VTE. With 
regards to stroke, elevated fibrinogen levels have been associated with ischemic stroke in a 
few cohort studies (Chuang et al., 2009; Fibrinogen Studies Collaboration et al., 2005; 
Siegerink et al., 2009) and case control studies (Kim et al., 2013; Zhang et al., 2013). In our 
study, genetically determined fibrinogen levels were consistently associated with 
cardioembolic stroke and small vessel disease.  While, for cardioembolic stroke, high 
genetically determined fibrinogen levels indicate a protective effect, small vessel stroke 
shows an increased risk associated with high genetically determined fibrinogen levels. High 
genetically determined total fibrinogen levels were associated with an increased risk of large 
artery stroke, but the association was not consistent across sensitivity analyses, suggesting 
that this observation does not reflect a causal effect and was instead driven by the inclusion 
of pleiotropic genetic instruments. 
 
Interpretation of γ′ fibrinogen MR results 
 
γ′ fibrinogen has a certain pro-thrombotic property: clots comprised of fibrin derived from γ′ 
fibrinogen have an altered structure, making them more resistant to fibrinolysis (Collet, 
Nagaswami, Farrell, Montalescot, & Weisel, 2004; Siebenlist et al., 2005). Perhaps more 
interesting is γ′ fibrinogen’s anti-thrombotic properties.  
γ′ fibrinogen has several anticoagulant properties that may explain the observed 
association of γ′ fibrinogen levels with VTE and certain ischemic stroke subtypes. First of all, 
the use of in vitro assays has suggested that γ′ fibrinogen may have an anticoagulant effect by 
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inhibiting factor V and factor XIII activation (Mosesson, 2003; Omarova et al., 2013). Also, 
γ′ fibrinogen has a high affinity for binding to thrombin, decreasing the amount of circulating 
thrombin (de Bosch, Mosesson, Ruiz-Saez, Echenagucia, & Rodriguez-Lemoin, 2002; Uitte 
de Willige et al., 2005). In binding to thrombin, γ′ fibrinogen reduces thrombin’s enzymatic 
ability to transform fibrinogen into a fibrin (Lovely, Boshkov, Marzec, Hanson, & Farrell, 
2007). Higher levels of γ′ fibrinogen would increase the number of thrombin binding sites, 
thereby decreasing risk of a clot. Because of thrombin’s role in activating platelets, γ′ 
fibrinogen’s inactivation of thrombin may also interfere with platelet aggregation (Lancellotti 
et al., 2008). γ′ fibrinogen’s anticoagulant properties give the expectation that increased 
levels of γ′ fibrinogen would result in decreased risk of thrombotic activity, such as VTE or 
ischemic stroke. 
 
Interpretation of total fibrinogen MR results 
Because of its role in clot formation and platelet aggregation, we would expect to see 
increased levels of total fibrinogen associated with increased risk of VTE and ischemic 
stroke (Mosesson, 2005). This would have been consistent with the modest but positive 
association between genetically observed total fibrinogen levels and coronary heart disease 
that has been observed in a recent MR (Ward-Caviness et al., 2018). For small vessel stroke 
this is what we observe. However, for large artery stroke, some sensitivity analyses indicate a 
positive effect and others indicate a negative effect. Inconsistencies across sensitivity 
analyses likely indicate the presence of pleiotropic variants in our genetic instrument, so we 
cannot interpret the effect of total fibrinogen levels on large artery stroke. High circulating 
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total fibrinogen levels were associated with lowered risk of VTE and cardioembolic stroke in 
our MR analysis. It is possible that the protective effect we are seeing in our results of total 
fibrinogen levels on VTE and cardioembolic stroke is due to γ′ fibrinogen or other 
confounding variables. Use of multivariable MR could help determine if total fibrinogen’s 
protective effect on VTE and cardioembolic stroke is being mediated by pleiotropic effects of 
the instrumental variables (Burgess & Thompson, 2015). 
Another reason why we may be seeing a protective effect is that higher levels of total 
fibrinogen may increase clot stabilization, preventing embolism (Wolberg et al., 2003). 
Pulmonary embolism, a manifestation of VTE, and cardioembolic stroke involve a clot 
breaking off and travelling to obstruct a blood vessel. 
 
Strengths & Limitations 
 
MR has several strengths compared to observational epidemiological research, including 
reduced susceptibility to confounding and reverse causation. In our MR, the effects of the 
genetic instruments on VTE and ischemic stroke subtypes were obtained using the largest 
GWAS available of these outcomes (Germain et al., 2015; Malik et al., 2018). Additionally, 
genetic instruments for fibrinogen came from the largest, most well-powered GWAS of 
fibrinogen currently available (de Vries et al., 2016). Instead of relying on a single genetic 
instrument, we combined information across multiple variants and loci, allowing us to further 
increase our power. 
Horizontal pleiotropy and linkage disequilibrium among the genetic instruments can 
lead to violation of critical assumptions of MR, which can lead to biased effect estimates 
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(Davey Smith & Hemani, 2014). To minimize the impact of horizontal pleiotropy among the 
genetic instruments, we used a wide variety of sensitivity analyses, each with their own 
assumptions about the pleiotropic nature of the instruments. Without knowing the number of 
pleiotropic SNPs and the extent to which they are violating this assumption, we cannot know 
which sensitivity analysis is most accurate. However, a broad consensus across sensitivity 
analyses suggests that the impact of pleiotropy is minimal, and this was the case for the 
majority of the reported associations. We used multiple variants at the fibrinogen gene cluster 
as genetic instruments, including uncorrelated instruments according to a threshold of r2= 
0.1. To control for potential bias related to residual LD (r2 < 0.1) among these variants, we 
performed a separate sensitivity analysis designed to account for LD, and this did not greatly 
impact our results.  
Caution should be exercised when interpreting these results, as effect estimates are 
given in per log(g/L) change for fibrinogen and per log(mg/dL) change for γ′ fibrinogen. A 
linear effect can therefore, not be assumed. Finally, the GWAS of γ′ fibrinogens was 
conducted in a much smaller sample size than the GWAS of fibrinogen levels. As a result, 
the only genome-wide significant locus was the fibrinogen gene cluster. However, this was 
the largest available GWAS of γ′ fibrinogen levels available at the time of the analyses. If a 
larger GWAS of γ′ fibrinogen levels becomes available in the future, this would increase the 
power to detect causal connections between γ′ fibrinogen and cardiovascular outcomes. 
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Conclusion 
We found that high genetically determined γ′ fibrinogen levels were associated with 
decreased risk of VTE, cardioembolic stroke, and large artery stroke, and that high 
genetically determined total fibrinogen was associated with decreased risk of VTE and 
cardioembolic stroke, but an increased risk of small vessel stroke. The association of γ′ 
fibrinogen levels with VTE and cardioembolic stroke was expected, given γ′ fibrinogen’s 
anticoagulant properties, but we did not anticipate the negative association of total fibrinogen 
levels with VTE and cardioembolic stroke. Further research is required to explain this 
apparent protective effect of total fibrinogen levels on these outcomes. 
 
CONCLUSION 
Our aim was to assess whether or not there is a causal association of γ′ fibrinogen and total 
fibrinogen levels on VTE and ischemic stroke. We hypothesized that increased levels of 
genetically determined γ′ fibrinogen decreases risk of VTE and ischemic stroke. Our 
hypothesis for γ′ fibrinogen was confirmed in our MR results and is most likely explained by 
γ′ fibrinogen’s anticoagulant properties. We also hypothesized that increasing total 
fibrinogen levels increases risk of VTE and ischemic stroke subtypes. The results from our 
MR indeed indicated such an effect on small vessel disease, but it also indicated a protective 
effect of total fibrinogen levels on VTE and cardioembolic stroke.  
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Strengths & Limitations 
We used the largest GWAS of fibrinogen, VTE, and ischemic stroke, so we were well-
powered to find effects (de Vries et al., 2016; Germain et al., 2015; Malik et al., 2018). Even 
though the γ′ fibrinogen GWAS was relatively small (Table 1), we still were able to detect 
an effect and received significant results (p < 0.05) in many of our analyses. By using 
information across multiple variants, instead of a single genetic instrument, we further 
increased our power, and reduced the chances that a single genetic variant with strong 
pleiotropic effect is driving our results. Multiple variants in our genetic instruments came 
from the fibrinogen gene cluster. Because these genes encode for fibrinogen, it is unlikely 
these variants have pleiotropic effects that do not involve fibrinogen (Omarova et al., 2013). 
However, we also used many sensitivity analyses to account for potential pleiotropy. 
Unfortunately, we do not know which variants are pleiotropic or the extent to which 
they are contributing to the effect estimate. We therefore do not know which of our 
sensitivity analyses is most appropriate. However, the consistency across the sensitivity 
analyses, present in many of our analyses (see Appendix C and E), suggest that if pleiotropy 
is present, it is either minimal or affects all sensitivity analyses similarly. The latter is 
unlikely since each sensitivity analyses is robust to different kinds of pleiotropy. Another 
limitation is that effect estimates were log transformed in the GWAS summary statistics we 
used for γ′ fibrinogen and total fibrinogen levels. Since it is not as straightforward to 
transform them back, interpretation of the causal effect sizes results is difficult.  
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Next steps 
Alternative explanations are needed to clarify why we observed a protective effect in our MR 
of genetically determined total fibrinogen levels on VTE, and cardioembolic stroke. Because 
γ′ fibrinogen is a part of total fibrinogen levels, we first need to assess if the protective 
association of total fibrinogen levels is mediated by γ′ fibrinogen levels. Additionally, 
because of fibrinogen’s role in inflammation, (Davalos & Akassoglou, 2012) we also need to 
assess whether the associations are confounded by pleiotropy involving C-reactive protein 
(CRP). We plan to use multivariable MR to adjust total fibrinogen levels for γ′ fibrinogen 
and CRP levels, separately, and see if a protective effect remains. Nevertheless, if pleiotropic 
effects on γ′ fibrinogen and CRP levels explain our results it is unclear why our sensitivity 
analyses showed such consistent effects. 
The protective association of total fibrinogen levels with VTE and cardioembolic 
stroke could instead be explained by an effect of fibrinogen on clot stabilization. 
Cardioembolic stroke and pulmonary embolism, which is part of the VTE definition, both 
involve embolism, in which part of the blood clot breaks off and travel to smaller blood 
vessels. Higher levels of total fibrinogen may increase clot stabilization, thereby preventing 
the events that result in pulmonary embolism and cardioembolic stroke (Wolberg et al., 
2003). To determine whether this is the case, we will attempt to perform separate MRs for 
pulmonary embolism and deep vein thrombosis. We expect the former to be affected by clot 
stabilization but not the latter. However, the INVENT Consortium did not analyze these 
outcomes separately (only jointly as VTE), and we will thus need to identify an additional 
data source (Germain et al., 2015). 
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γ′ fibrinogen’s protective effect on VTE, cardioembolic stroke, and large artery stroke 
can pave the way for alternative therapies to be produced, other than typical anticoagulant 
medications that have significant risks. However, what remains unclear is whether increased 
absolute levels of γ′ fibrinogen or increased ratio of γ′ fibrinogen to total fibrinogen levels are 
more important in reducing risk of these outcomes (Uitte de Willige et al., 2005). To assess 
this, a GWAS of γ′ fibrinogen to total fibrinogen ratio should be performed and then used in 
MR analyses, so that we can deduce which has the greater impact. Unfortunately, γ′ 
fibrinogen and total fibrinogen levels were not assessed in the same visit among ARIC study 
participants, so we could not use the ARIC study to perform this additional analysis. More in 
vivo animal studies should be performed to assess the efficacy and safety of increasing γ′ 
fibrinogen levels (or the γ′ fibrinogen to total fibrinogen ratio) before considering its 
potential as an alternative for anticoagulant medications.  
Finally, as total fibrinogen levels have already been implicated in causing coronary 
heart disease (Ward-Caviness et al., 2018) our MR suggests the need to evaluate γ′ fibrinogen 
levels as well, in assessing causal effect on cardiovascular outcomes, such as coronary heart 
disease.   
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APPENDICES 
Appendix A: Manhattan plot for the genome-wide association of γ′ fibrinogen levels.  
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Appendix B: Causal effect estimates produced by individual genetic instruments for γ′ 
fibrinogen 
 
Figure 1: γ ′ fibrinogen levels on VTE  
 
 
 
 
 
Figure 2: γ′ fibrinogen on cardioembolic stroke 
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Figure 3: γ′ fibrinogen on large artery stroke 
 
 
 
 
 
 
 
Figure 4: γ′ fibrinogen on small vessel stroke 
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Figure 5: γ′ fibrinogen on any ischemic stroke 
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Appendix C: Sensitivity analyses for Mendelian randomization of γ′ fibrinogen levels 
 
Figure 1: γ′ fibrinogen levels on venous thromboembolism 
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Figure 2: γ′ fibrinogen levels on cardioembolic stroke 
 
 
 
 
Figure 3: γ′ fibrinogen levels on large artery stroke 
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Figure 4: γ′ fibrinogen levels on small vessel stroke 
 
 
 
 
Figure 5: γ′ fibrinogen levels on any ischemic stroke 
 
 
32 
 
Appendix D: Causal effect estimates produced by individual genetic instruments for total 
fibrinogen levels. 
 
Figure 1: Total fibrinogen levels on venous thromboembolism
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Figure 2: Total fibrinogen levels on cardioembolic stroke 
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Figure 3: Total fibrinogen levels on large artery stroke 
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Figure 4: Total fibrinogen levels on small vessel stroke 
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Figure 5: Total fibrinogen levels on any ischemic stroke 
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Appendix E: Sensitivity analyses for Mendelian randomization of total fibrinogen levels 
Figure 1: Total fibrinogen levels on venous thromboembolism 
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Figure 2: Total fibrinogen levels on cardioembolic stroke 
 
Figure 3: Total fibrinogen levels on large artery stroke 
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Figure 4: Total fibrinogen levels on small vessel stroke 
 
Figure 5: Total fibrinogen levels on any ischemic stroke 
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